Energetic, structural, and antimicrobial analyses of β-lactam side chain recognition by β-lactamases  by Caselli, Emilia et al.
Research Paper
Energetic, structural, and antimicrobial analyses of L-lactam
side chain recognition by L-lactamases
Emilia Caselli a;b; 1, Rachel A. Powers a; 1, Larry C. Blasczcak c,
Chyun Yeh Earnest Wu c, Fabio Prati b; 2, Brian K. Shoichet a; *
aDepartment of Molecular Pharmacology and Biological Chemistry, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA
bDipartimento di Chimica, Universita' degli Studi di Modena, Via Campi 183, Modena, Italy
cInfectious Diseases Research, Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285, USA
Received 18 September 2000; revisions requested 13 October 2000 revisions received 24 October 2000; accepted 30 October 2000
First published online 19 December 2000
Abstract
Background: Penicillins and cephalosporins are among the most
widely used and successful antibiotics. The emergence of resistance
to these L-lactams, most often through bacterial expression of
L-lactamases, threatens public health. To understand how
L-lactamases recognize their substrates, it would be helpful to
know their binding energies. Unfortunately, these have been
difficult to measure because L-lactams form covalent adducts with
L-lactamases. This has complicated functional analyses and
inhibitor design.
Results : To investigate the contribution to interaction energy of
the key amide (R1) side chain of L-lactam antibiotics, eight
acylglycineboronic acids that bear the side chains of characteristic
penicillins and cephalosporins, as well as four other analogs, were
synthesized. These transition-state analogs form reversible adducts
with serine L-lactamases. Therefore, binding energies can be
calculated directly from Ki values. The Ki values measured span
four orders of magnitude against the Group I L-lactamase AmpC
and three orders of magnitude against the Group II L-lactamase
TEM-1. The acylglycineboronic acids have Ki values as low as
20 nM against AmpC and as low as 390 nM against TEM-1. The
inhibitors showed little activity against serine proteases, such as
chymotrypsin. R1 side chains characteristic of L-lactam inhibitors
did not have better affinity for AmpC than did side chains
characteristic of L-lactam substrates. Two of the inhibitors
reversed the resistance of pathogenic bacteria to L-lactams in cell
culture. Structures of two inhibitors in their complexes with
AmpC were determined by X-ray crystallography to 1.90 Aî and
1.75 Aî resolution; these structures suggest interactions that are
important to the affinity of the inhibitors.
Conclusions: Acylglycineboronic acids allow us to begin to
dissect interaction energies between L-lactam side chains and
L-lactamases. Surprisingly, there is little correlation between the
affinity contributed by R1 side chains and their occurrence in
L-lactam inhibitors or L-lactam substrates of serine L-lactamases.
Nevertheless, presented in acylglycineboronic acids, these side
chains can lead to inhibitors with high affinities and specificities.
The structures of their complexes with AmpC give a molecular
context to their affinities and may guide the design of anti-
resistance compounds in this series. ß 2001 Elsevier Science Ltd.
All rights reserved.
Keywords: Interaction energy; Transition-state analog; Antibiotic resis-
tance; Structure-based inhibitor design; Drug design
1. Introduction
L-Lactamases catalyze the hydrolysis of L-lactam anti-
biotics, such as penicillins and cephalosporins, and are the
most widespread bacterial resistance mechanism to these
drugs [1]. Partly in response to the emergence and spread
of L-lactamases, many L-lactam derivatives have been de-
veloped; over 40 are currently used in clinical practice.
These analogs preserve the L-lactam core of the drug but
explore diverse functionality o¡ the C6(7) position of the
penicillin/cephalosporin ring, in what we will refer to as
the R1 side chain (Fig. 1). The di¡erent R1 side chains
confer di¡erent pharmacological pro¢les, di¡erent bacter-
ial spectra of action, and di¡erent levels of resistance to
L-lactamases. Whereas early penicillins and cephalosporins,
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such as penicillin G and cephalothin (Fig. 1), are rapidly
inactivated by L-lactamases, later agents, such as cloxacil-
lin and ceftazidime, are relatively inert to, or indeed inhib-
it, these enzymes. Despite intense study, it has been di⁄-
cult to understand how these seemingly de¢ning R1 side
chains contribute to L-lactam^L-lactamase recognition.
The problem lies in the covalent bond that L-lactams
form with Group I and Group II L-lactamases. In these
enzymes, the catalytic serine attacks the lactam bond to
form an acyl-adduct (Fig. 2); this step is rapid for L-lac-
tamases. The acyl-adduct is then hydrolyzed in a second
step; deacylation is rate determining for Group I L-lac-
Fig. 1. Clinically used penicillins (I^V) and cephalosporins (VI^VIII)
Fig. 2. L-Lactam hydrolysis by serine L-lactamases. The deacylation step is slow for L-lactam inhibitors and poor substrates. B represents the general
base in the mechanism.
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tamases and for poor substrates and inhibitors of both
classes of enzyme. The covalent nature of the acyl-adduct,
and its rapid formation, means that binding is e¡ectively
irreversible; binding equilibria are not readily available
through steady state kinetics [2]. This precludes easy en-
ergetic analyses, which assume reversible equilibria. In
L-lactamases, Km values are convolutions of irreversible
acylation and deacylation rates with reversible on and
o¡ rates, and IC50 values are often dominated by rates
Fig. 3. Comparison between the deacylation high-energy intermediate of
a penicillin in a serine L-lactamase and the transition-state analog
formed by an acylglycineboronic acid and the same enzyme.
Table 1
Ki (WM) values of acylglycineboronic acids against AmpC and TEM-1
Compounds 6 to 10 bear side chains common to the penicillins; compounds 11 to 14 bear side chains common to the cephalosporins. 7 is common to
other L-lactams: cefoxitin, nitroce¢n, and cephaloridine. aNot measured. bDi¡erential free energy of binding relative to compound 5 at 298 K. Positive
values indicate improved a⁄nity.
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of deacylation. Rarely do they re£ect binding energies or
inhibitor^enzyme complementarity in any simple way
[3,4]. Indeed, both structural [5,6] and stability [7] studies
have suggested that some L-lactam inhibitors of L-lac-
tamases ¢t the enzyme poorly ^ their inhibitory properties
derive entirely from their ability to form an acyl-adduct
and then block attack by the hydrolytic water. On the
other hand, some R1 side chains undoubtedly ¢t the en-
zymes well. Identifying, far less quantifying, which ones do
so has been di⁄cult.
To investigate the energetic bases of L-lactam functional
group recognition by L-lactamases, we have synthesized
acylglycineboronic acids that bear the R1 side chains of
eight characteristic penicillins and cephalosporins (Fig. 1).
Boronic acids are transition-state analog inhibitors of
Group I and Group II L-lactamases [8^14] (Fig. 3). Unlike
L-lactams, they form reversible adducts with these en-
zymes; binding energies thus can be calculated directly
from Ki values. By comparing the a⁄nities of di¡erent
acylglycineboronic acids, we can determine what the dif-
ferent R1 side chains contribute to binding to a L-lactam-
ase. By comparing the a⁄nities to a Group I L-lactamase,
AmpC, and a Group II L-lactamase, TEM-1, we can in-
vestigate di¡erential recognition between characteristic
representatives of the two most widespread classes of
L-lactamases. To give the binding energies a molecular
context, we have determined the structures of two of these
inhibitors in their complexes with AmpC L-lactamase by
X-ray crystallography. Comparing one of these structures
with that of its L-lactam counterpart in complex with
AmpC [6] allows us to investigate how interactions with
the R1 side chain di¡er between the acylated ground state
and the presumptive deacylation high-energy intermediate.
To explore the application of acylglycineboronic acids to
reversing L-lactamase-mediated resistance at the level of
cell culture, we have investigated their ability to act syn-
ergistically with L-lactams against resistant, pathogenic
bacteria.
2. Results
2.1. Synthesis
Six acylglycineboronic acids (6, 7, 8, 9, 10, 11, 12) were
synthesized through nitrogen displacement with
LiN[Si(CH3)3]2 on chloromethylboronic acid pinacol ester
1, followed by deprotection with equimolar methanol, and
¢nally condensation with an acylchloride. The yield of
these two-step syntheses varied from 62 to 92%. Slight
changes to this general scheme were performed to synthe-
size 5, 13, and 15. Deprotection of 4 was performed with
Table 2
Selectivity of 3 and 15 for AmpC and TEM-1 L-lactamases versus serine
proteases
Enzyme IC50 (WM) for 3 IC50 (WM) for 15
AmpC 17 0.081
TEM-1 247 2.4
K-Chymotrypsin s 2 000b 2 000
L-Trypsin s 400a s 400a
Elastase s 400a 450
aNo inhibition was observed at 100 WM. The IC50 values assume that
inhibition was no greater than 20% at this concentration.
bNo inhibition was observed at 500 WM. The IC50 values assume that
inhibition was no greater than 20% at this concentration.
Table 3
Data collection and re¢nement statistics
9/AmpC complex 11/AmpC complex
Cell constants (Aî ; ‡) a = 118.36 b = 77.57 c = 97.46; L= 116.18 a = 118.11 b = 77.83 c = 97.32; L= 115.83
Resolution (Aî ) 1.75 1.90
Unique re£ections 79 142 58 505
Total re£ections 287 631 176 832
Rmerge (%) 6.4 (13.9)a 6.3 (17.2)a
Completeness (%) 98.6 (94.6)a 93.6 (94.5)a
GIf/GcI f 12.9 14.2
Resolution range for re¢nement (Aî ) 20^1.75 (1.79^1.75 Aî )a 20^1.90 (1.94^1.90 Aî )a
Number of protein residues 716 716
Number of water molecules 499 415
RMSD bond lengths (Aî ) 0.014 0.013
RMSD bond angles (‡) 1.781 1.719
R-factor (%) 19.6 19.4
Rfree (%) 21.8b 22.7b
Average B-factor, protein atoms (Aî 2) 30.0c 32.0c
Average B-factor, protein atoms (Aî 2, monomer 1 only) 29.9 31.8
Average B-factor, inhibitor atoms (Aî 2) 40.6c 41.0c
Average B-factor, inhibitor atoms (Aî 2, monomer 1 only) 36.8 39.9
aValues in parentheses are for the highest resolution shell used in re¢nement.
bRfree was calculated with 10% of re£ections set aside randomly.
cValues cited were calculated for both molecules in the asymmetric unit.
CHBIOL 49 7-2-01 Cyaan Magenta Geel Zwart
20 Chemistry & Biology 8/1 (2001) 17^31
acetic acid; reaction with acetic anhydride gave 5 in 60%
yield. The condensation of compound 12 with 4-mercap-
topyridine gave 13 in 90% yield. Compound 14 was ob-
tained by preactivating (Z)-2-amino-K-[1-(tert-butoxycar-
bonyl)-1-methylethoxyimino]-4-thiazoleacetic acid as a
mixed anhydride followed by reaction with the depro-
tected 4. The tert-butoxycarbonyl group of 14 was re-
moved with TFA to give 15 in 64% yield over three steps.
This general synthetic scheme seems well suited to attach-
ing the R1 side chains of L-lactams to glycineboronic
acids.
2.2. Binding constants
The di¡erential a⁄nities of the acylglycineboronic acids
allowed us to determine the contributions of the R1 side
chain of L-lactams to molecular recognition by the various
enzymes. Against the Group I L-lactamase AmpC, the Ki
values spanned a 1000-fold range, from 20 nM to 19 WM
(Table 1). Comparing the minimal amide side chain of 3
(Ki 4.8 WM) to methylboronic acid (Ki 1 mM) or to boric
acid (Ki 2.8 mM) suggests that the amide group itself
contributes 3.2 kcal/mol to binding in this series (using
vvGbind =3RTlnK1/K2). Comparing the a⁄nity of 3 to
compounds with more elaborate side chains, such as the
ceftazidime analog 15 (Ki 20 nM), suggests that variations
distal to the amide group can contribute at least 4.0 kcal/
mol further to the interaction energy with AmpC.
The acylglycineboronic acids bound less tightly to the
Group II L-lactamase TEM-1 than they did to AmpC
(Table 1). Against TEM-1, Ki values varied from 0.39 to
162 WM. These values were 8^40-fold worse (higher) than
with AmpC. As with AmpC, compound 15, bearing the
ceftazidime side chain, was the most active compound
against TEM-1 (Ki 0.39 WM).
Fig. 4. Stereoview of 2Fo3Fc electron density of the re¢ned models for AmpC complexes of (A) compound 9 and (B) compound 11. The density is
contoured at 1 s. Carbon atoms are colored orange, oxygen atoms red, nitrogen atoms blue, sulfur atoms green, chlorine atoms magenta, and boron
atoms purple. These ¢gures were generated using Turbo [38].
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2.3. Selectivity testing
Compound 3, bearing the minimal amide side chain,
and compound 15, bearing the relatively elaborate ceftaz-
idime side chain, were tested for L-lactamase selectivity
versus the serine proteases K-chymotrypsin, L-trypsin,
and elastase (Table 2). Compound 3 showed no activity
up to 100 WM against any of the proteases. Compound 15
had an IC50 of 82 nM for AmpC and a projected IC50 of
2 mM for K-chymotrypsin, 450 WM for elastase, and no
measurable activity against L-trypsin. These assays were
performed at a similar ratio of substrate concentration
to Km for each enzyme.
2.4. X-ray crystallographic structure determination
The structures of both 9 and 11 in complex with the
Group I L-lactamase AmpC were determined to 1.75 Aî
and 1.90 Aî resolution, respectively (Table 3). The location
of the inhibitor in each complex was unambiguously iden-
ti¢ed in the initial Fo3Fc di¡erence maps when contoured
at a level of 3 c. Simulated annealing omit maps of the
re¢ned models agree well with the placement of the inhib-
itors in the active sites (not shown).
The quality of each of the models was analyzed with the
program Procheck [15]. For the model of the complex of 9
with AmpC, 92.9% of the non-proline, non-glycine resi-
Table 4
Interactions in complexed and native AmpC L-lactamase
aDistances are for monomer 1 of the asymmetric unit. Monomer 1 was chosen because electron density for the inhibitors was better and average B-fac-
tors for the inhibitor atoms were 3^8 Aî 2 lower in monomer 1 versus monomer 2; the respective distances di¡er only slightly between the two mono-
mers. The RMSD for the CK atoms of the two monomers is 0.22 Aî for 9/AmpC and 0.23 Aî for 11/AmpC. The RMSD for the inhibitor atoms between
the two molecules is 0.204 Aî for 9/AmpC and 0.271 Aî for 11/AmpC when the CK atoms are overlaid. bDistances are for monomer 2 of the asymmetric
unit. cNot present. dIn the native structure, Wat402 is called Wat387.
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dues were in the most favored region of the Ramachan-
dran plot (7.1% in the additionally allowed region), and
for the complex of 11 with AmpC, 91.9% of the non-pro-
line, non-glycine residues were in the most favored region
(8.1% in the additionally allowed region). The structures
have been deposited with the PDB as 1FSY (complex with
9) and 1FSW (complex with 11).
In both structures electron density is observed connect-
ing OQ of the catalytic Ser64 to the boron atom of the
inhibitors (Fig. 4). The geometry around the boron is tet-
rahedral, as expected. The O1 of the boronic acid is within
good hydrogen-bonding distance of the backbone nitro-
gens of Ser64 and Ala318 and also the backbone oxygen
of Ala318 (Table 4). These interactions are highly con-
served in L-lactamase structures with transition-state ana-
logs [10,12^14,16]. The O2 of the boronic acid, which
probably represents the position of the deacylating water
in the high-energy intermediate [6,13], hydrogen bonds
with the putative catalytic base Tyr150 [16,17] (Table 4).
Two well-ordered water molecules are also observed in the
region of the tetrahedral center of each complex, as seen in
a previous structure of AmpC in complex with a boronic
acid inhibitor [13]. The ¢rst water (Wat402) interacts with
O2 of the boronic acid, OQ1 of Thr316, and another water
molecule (Wat506). The second water (Wat403) interacts
with Wat402, as well as with ON1 of Asn346 and NR1 of
Arg349. In the complex with 9, Wat403 is also within
hydrogen bonding distance to another water molecule
(Wat549) (Table 4).
In the crystal structures, the amide groups in the acyl-
glycineboronic acids are placed close to where the analog-
ous R1 side chain amide is placed in the structures of
complexes between L-lactams and L-lactamases [6,18,19].
The amide groups in both the transition-state analog
structures and the L-lactam acyl-adducts make similar in-
teractions with the enzymes. In the structure of 11 with
AmpC, the carbonyl oxygen (O6) of the amide group in-
teracts with NN2 of Asn152 (2.8 Aî ) and NO2 of Gln120
(2.9 Aî ) (Table 4); both residues are completely conserved
among Group I L-lactamases. In the complex of 9 with
AmpC, only the interaction between NN2 of Asn152 and
O6 is seen (2.5 Aî ). Gln120 appears unable to hydrogen
bond with O6 due to a steric con£ict that would occur
with the chlorine atom of the inhibitor; instead, this res-
idue has rotated by 119‡ around M2, away from the chlor-
ine atom. In the complex with 9, an interaction is also
observed between Ala318O and N4 (3.3 Aî ) (Table 4).
The unique part of the R1 side chain of compound 11,
the thiophene ring, appears to make few interactions with
AmpC. Di¡erence density suggests that this ring can as-
sume two conformations, which di¡er from each other by
a 180‡ rotation around the C7^C8 bond. In each of the
conformations, the atoms to which the thiophene is near-
est are Thr319C and Asn343NN2; the distances are be-
tween 3.4 and 3.5 Aî . The nearest atom to the sulfur of
the thiophene ring in one conformation is the CL of
Ala318 (3.7 Aî ); there is also a water molecule (Wat745)
3.4 Aî away from the sulfur in this conformation. In the
Fig. 5. Key polar interactions observed between AmpC and (A) compound 9 and (B) compound 11. Dashed yellow lines indicate hydrogen bonds.
Atoms are colored as in Fig. 4, except for the inhibitors where carbon atoms are colored gray in 9 and magenta in 11. Cyan spheres represent water
molecules. Interaction distances are listed in Table 4. These ¢gures were generated with MidasPlus [39].
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second conformation, the sulfur is nearest to NO2 of
Gln120 (4.3 Aî ) and is close to two water molecules
(Wat744, 3.8 Aî and Wat743, 3.9 Aî ).
In the complex of 9 with AmpC, O10 of the isoxazole
ring interacts with a water molecule (Wat569, 3.1 Aî ). The
exocyclic methyl group (C9) packs against the aryl ring of
Tyr221. The chlorobenzyl ring of the inhibitor is located in
a hydrophobic pocket formed by residues Leu119 and
Leu293. The CL of Ala318 also contributes to burial of
this ring. The distances range from 3.6 Aî (from C18 to CL
of Ala318) to 4.3 Aî (from C15 to CN2 of Leu119 and to
CN1 of Leu293). This ring is also near residues Asn289 and
Asn343 and appears to make van der Waals interactions
with these residues. As mentioned above, the chlorine
atom is placed near Gln120 (3.8 Aî ).
2.5. Microbiology
The minimum inhibitory concentration (MIC) of cef-
tazidime and cefotaxime against the EB5 strain of Entero-
bacter cloacae, which does not produce a Group I L-lac-
tamase, were 0.4 Wg/ml and 0.25 Wg/ml, respectively.
Administered alone, neither 10 nor 15 had measurable
activity; additionally there was no synergy observed
against this strain when these compounds were adminis-
tered with either ceftazidime or cefotaxime. Similarly,
compound 15 had no activity by itself against Staphylo-
coccus aureus strain V41; the MIC of compound 10 alone
was 128 Wg/ml against this strain. Against strain 265A of
E. cloacae, which hyper-produces a Group I L-lactamase,
the MIC values of ceftazidime and cefotaxime rose to 256
and 128 Wg/ml, respectively. Both compounds 10 and 15
showed synergy with these L-lactams against this strain.
Compound 15 reduced the MIC of ceftazidime by 256-fold
at 32 Wg/ml of the inhibitor (data not shown) and reduced
the MIC of cefotaxime by 128-fold at the same concen-
tration (Table 5). Both inhibitors also showed synergy
with amoxicillin against S. aureus expressing a Group II
L-lactamase (Table 5).
Disk di¡usion plate assays were performed to study the
e¡ects of compounds 10 and 15 on the e⁄cacy of the
L-lactam ceftazidime. As expected, the plate containing
E. cloacae that does not produce a L-lactamase shows a
large inhibition halo surrounding the upper disks that con-
tain ceftazidime. The lower disks, which contain com-
pound 10 (right) or 15 (left), have no e¡ect on the inhibi-
tion halo of ceftazidime, nor do they show any inhibition
halos of their own (Fig. 6A). The plate containing E. clo-
acae that hyper-produce a Group I L-lactamase shows
greatly reduced inhibition halos surrounding the upper
disks containing ceftazidime, and in contrast to the pre-
Fig. 6. Synergistic e¡ects of compounds 15 and 10 observed with the
L-lactam ceftazidime. (A) E. cloacae strain EB5 (L-lactamase negative).
Each of the upper disks contains 25 Wg ceftazidime. The lower disk on
the left contains 100 Wg compound 15, and the lower disk on the right
contains 100 Wg compound 10. (B) E. cloacae strain 265A (Group I
L-lactamase hyper-producer). Each of the upper disks contains 50 Wg
ceftazidime. The lower disk on the left contains 100 Wg of 15, and the
lower disk on the right contains 100 Wg of 10.
Table 5
Synergy of compounds 10 and 15 with L-lactams against L-lactamase-producing bacteria
E. cloacae 265A S. aureus V41
Cefotaxime MICa
(Wg/ml)
10
(Wg/ml)
Cefotaxime MICa
(Wg/ml)
15
(Wg/ml)
Amoxicillin MICa
(Wg/ml)
10
(Wg/ml)
Amoxicillin MICa
(Wg/ml)
15
(Wg/ml)
128 0 128 0 64 0 64 0
64 2 64 2 64 2 64 2
64 4 64 4 32 4 64 4
64 8 16 8 32 8 32 8
32 16 2 16 16 16 32 16
16 32 1 32 8 32 32 32
8 64 0.5 64 2 64 16 64
4 128 0.5 128 0 128 8 128
aThe MIC of the L-lactam, either cefotaxime or amoxicillin, in the presence of the adjacent concentration of inhibitor.
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vious plate, the inhibition halos in the regions between the
two disks are substantially increased (Fig. 6B). This in-
crease in the size of the inhibition halos between the two
disks indicates that each compound has a synergistic e¡ect
when coupled with ceftazidime.
3. Discussion
The acylglycineboronic acids span ¢ve orders of magni-
tude in a⁄nity for AmpC, from a dissociation constant of
2.8 mM for boric acid itself to 20 nM for the ceftazidime
analog 15 (Table 1). This suggests that the R1 side chains
of L-lactams can make considerable contributions to a⁄n-
ity for L-lactamases. The result is unexpected, if only be-
cause the e¡ect of R1 side chains on a⁄nity has previously
been largely unknown. The compounds appear to be se-
lective for L-lactamases, especially Group I L-lactamases
resembling AmpC, showing little a⁄nity for serine pro-
teases that are known to be inhibited by peptide boronic
acids [20] (Table 2). This is consistent with the speci¢c
recognition of the R1 side chains by serine L-lactamases.
The di¡erential energies between compounds allow us to
interpret the interactions that we observe in the crystal
structures of two of these inhibitors, and by analogy, those
observed in other L-lactam complexes. Additionally, com-
paring the X-ray crystal structure of a transition-state ana-
log complex with that of an acyl-enzyme intermediate sug-
gests how recognition of the R1 side chain changes
between the transition state and the acylated ground state
in Group I L-lactamases.
An important contribution to a⁄nity comes from the
amide group common to all the inhibitors. Comparing
compound 3 to methylboronic acid suggests that this
amide contributes 3.2 kcal/mol to the free energy of bind-
ing. This group represents the C6(7) R1 amide that is
ubiquitous among L-lactam antibiotics (Fig. 1). In pre-
vious structures with L-lactams, the amide oxygen of the
side chain has been observed to hydrogen bond to the side
chain of the conserved Asn152 (Asn132 in Group II
L-lactamases). The amide nitrogen of the R1 side chain
has been observed to hydrogen bond to the main chain
carbonyl of residue 318 in Group I L-lactamases (residue
237 in Group II L-lactamases) [6,16,18,19,21]. In the X-ray
crystal structures of 9 and 11 in complex with AmpC, the
R1 amide hydrogen bonds to Asn152 (Fig. 5, Table 4).
The hydrogen bonding interaction with Ala318 is observed
in the structure of AmpC with 9 but not with 11. The
hydrogen bond between the ligand amide nitrogen and
the backbone carbonyl of residue 318/237 may not be as
well conserved structurally as that of Asn152/Asn132 with
the ligand amide oxygen [6,10].
The distal parts of the R1 side chain, which have been
the principle focus of design and modi¢cation of semisyn-
thetic L-lactam antibiotics, also contribute to binding af-
¢nity. Dissociation constants vary from 700 nM for 7,
which bears the penicillin V side chain, to 20 nM for 15,
which bears the ceftazidime side chain (Table 1). By com-
parison to the acetamido side chain in compound 5 (Ki 18
WM), the contribution to a⁄nity for each group can be
determined. For instance, the ceftazidime side chain con-
tributes 4.0 kcal/mol in di¡erential a⁄nity compared to 5.
Intriguingly, L-lactam side chains that are associated with
inhibitors of AmpC do not necessarily have higher a⁄n-
ities than boronic acids bearing substrate side chains. For
instance, cloxacillin is an inhibitor of AmpC, whereas cef-
tazidime is a substrate for the enzyme, albeit a poor one;
nevertheless, the ceftazidime analog 15 binds 10-fold better
to the enzyme than does the cloxacillin analog 9. Similarly,
compound 11, which bears the side chain of the very good
substrate cephalothin, binds only two-fold less well than
the cloxacillin analog 9.
Although Group I and Group II L-lactamases are mech-
anistically related, the two enzyme groups have di¡erent
substrate preferences and inhibitor pro¢les. To investigate
di¡erential recognition between these two classes of L-lac-
tamases, the a⁄nity of several of the acylglycineboronic
acid inhibitors was determined for the characteristic
Group II L-lactamase, TEM-1. Overall, there is a mono-
tonic relationship between the a⁄nity of acylglycinebor-
onic acids for AmpC and for TEM-1, with the a⁄nities
for TEM-1 being 8^40-fold worse. TEM-1, traditionally
known as a penicillinase, does not appear to be more
selective for R1 side chains associated with penicillins
than does the cephalosporinase AmpC for the side chains
of R1 side chains associated with cephalosporins (Table 1).
To the extent that Group I and Group II L-lactamases are
selective for cephalosporins and penicillins [3], respec-
tively, this does not seem to owe to di¡erences in the R1
side chains associated with each of these classes of drugs.
The greater a⁄nity of the acylglycineboronic acids for
AmpC versus TEM-1 suggests that the R1 side chain con-
tributes more to recognition in Group I L-lactamases than
it does in Group II L-lactamases. This suggestion is con-
sistent with residue substitution and inhibition studies in
these enzymes. Whereas the R1-amide recognition residue
Asn132 of Group II L-lactamases can be substituted with
an aspartate or a serine with little loss of enzyme activity
[22], the analogous N152D AmpC mutant enzyme loses
four orders of magnitude of activity [23]. Also, the C3(4)
carboxylate, on the other side of the L-lactam ring, con-
tributes strongly to recognition of L-lactams by Group II
L-lactamases but not to Group I L-lactamases [24]. The
importance of this carboxylate for Group II L-lactamases
is reinforced by a comparison of the activity against TEM-
1 of compound 6 with that of an analogous boronic acid,
(1R)-1-phenylacetamido-2-(3-carboxyphenyl)-ethylboronic
acid. The latter compound has the same R1 side chain as 6
but also has a carboxylate resembling the C3 carboxylate
in penicillins [14]. The carboxylate-containing boronic acid
has a Ki of 5.9 nM against TEM-1, whereas compound 6
has a Ki of 13.8 WM.
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Boronic acids mimic the tetrahedral geometry of the
transition state of Group I L-lactamases [6,13,25], and it
is interesting to compare their placement of the R1 side
chains with that of the L-lactam acyl-adduct structures.
When we overlap the structure of the AmpC/9 complex
with that of a mutant AmpC (Q120L/Y150E) bound to
cloxacillin [6] in an acyl-adduct, we observe that the two
R1 side chains are placed similarly in both structures (Fig.
7). The RMSD between the two side chains is 0.9 Aî , and
most of the interactions are maintained. The greatest po-
sitional di¡erences are at the amide nitrogen at the begin-
ning of the R1 side chain, but even here the transition-
state analog and the acyl-adduct maintain the same inter-
actions. On the part of the enzyme, there is little reorgan-
ization in the active site region. The RMSD between the
CK atoms of conserved residues in the active sites (Ser64,
Lys67, residue 150, Asn152, Tyr221, Lys315, and Ala318)
of transition-state structure and the acyl-enzyme structure
is 0.17 Aî (0.44 Aî for all atoms of the above residues except
residue 150, whose identity di¡ers between the mutant and
wild type enzymes). We make two inferences based on this
comparison. First, at least for the cloxacillin group, the
presence of rest of the L-lactam has little e¡ect on the
positioning of the R1 side chain. Second, the similarity
of the acyl-adduct ground state to the transition-state ana-
log suggests that progress along the reaction requires little
reorganization in the R1 side chain or in the residues with
which it interacts. There may be little di¡erential stabiliza-
tion between the acylated ground state and the transition
state in the region of the R1 side chain.
Where the transition-state analog complexes di¡er most
from the L-lactam acylated ground-state complexes is in
the region of the tetrahedral center. In moving from the
planar ester center to the tetrahedral boronic acid, a hy-
drogen bond is gained between the O2 hydroxyl of the
boronic acid and the hydroxyl of Tyr150. The O2, which
appears to represent the position of the deacylating water
in the high-energy intermediate [13], hydrogen bonds with
Wat402. This water is conserved in native [12], acyl-en-
zyme [6], and transition-state analog structures [13], and
it may identify the region from where the deacylating
water attacks the acyl-adduct [6]. The O1 atom of the
boronic acid, which represents the position of what was
the lactam carbonyl oxygen in the acyl-enzyme intermedi-
ate [6], moves to pick up a hydrogen bond with the back-
bone oxygen of Ala318 in the tetrahedral adduct. This
may be consistent with the status of this oxygen as a
hydroxyl in the high-energy intermediate [12,13]. The over-
all picture that emerges is that, in moving from an acylat-
ed ground state to a transition-state analog complex,
structural change is largely localized to the transition
from a planar to a tetrahedral center in the ligand itself.
Once very e¡ective, third-generation cephalosporins
such as ceftazidime and cefotaxime have become largely
useless against hospital pathogens such as E. cloacae be-
cause of the hyper-production of Group I L-lactamases.
Given the high a⁄nity of compounds 10 and 15 in enzyme
assays, it seemed worthwhile to investigate their ability to
reverse this resistance. Both inhibitors were synergistic
when used in combination with the widely used third-gen-
eration cephalosporins ceftazidime (Fig. 6) and cefotaxime
(Table 5). At high concentrations of 15, the MIC values of
these antibiotics were reduced by two orders of magnitude,
close to the levels of non-resistant strains. The synergistic
e¡ect is perhaps shown most compellingly in the disk dif-
fusion assays (Fig. 6). Against non-resistant E. cloacae,
compounds 10 and 15 had no obvious e¡ect, whereas
against resistant strains of the same bacteria, these com-
pounds showed an unmistakeable synergy. Both inhibitors
were also active against an isolate of S. aureus expressing a
Group II L-lactamase, although e⁄cacies were lower. The
ability of 10 and 15 to reverse L-lactamase-based resis-
tance, especially against the nosocomial pathogen E. clo-
acae, suggests that these compounds may be useful leads
for the design of new agents to reverse bacterial resistance
to L-lactams.
The X-ray crystal structures of AmpC with 9 and 11
may guide further inhibitor design. In the complex of 9
with AmpC, non-polar complementarity is achieved
through interactions with residues Leu119, Leu293, and
Ala318. The methyl group of the isoxazole ring of 9 forms
van der Waals interactions with the Tyr221. The function
of this conserved residue is unknown, but it often forms
aromatic polar or stacking interactions with substrates [6]
and inhibitors [6,13]. In both complexes, the R1 side
chains only ¢ll part of the enzyme cleft, leaving uncom-
plemented polar residues such as Asp123, Arg204, and
Ser212. Interactions with some of these residues may
help explain the increased a⁄nity of 15, which is the
Fig. 7. Overlay of the structure of cloxacillin in complex with the
AmpC mutant enzyme Q120L/Y150E and of the transition-state analog
9 in complex with wild type AmpC. Carbon atoms of cloxacillin are col-
ored green, and carbon atoms of 9 are colored gray.
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most polar and the most active of the compounds tested.
Intriguingly, Ser212 is just proximal to a site of a tandem
insertion in a related Group I L-lactamase that leads to a
mutant enzyme resistant to ceftazidime [26], the L-lactam
analog of 15. It may be possible to improve polar com-
plementarity in this series to increase inhibition and spec-
i¢city.
4. Signi¢cance
Penicillins and cephalosporins have had an enormous
impact on human health. Unfortunately, the e⁄cacy of
these antibiotics is threatened by the emergence of L-lac-
tamases. To understand how L-lactamases recognize L-lac-
tam substrates and L-lactam inhibitors, it would be helpful
to know what their binding energies are, but these have
been di⁄cult to measure because L-lactams form covalent
adducts with L-lactamases. The reversible binding of the
transition-state analog acylglycineboronic acids allows us
to begin to dissect the energetic bases for recognition of
the ubiquitous R1 side chains of L-lactam antibiotics by
L-lactamases. We observe little relationship between a⁄n-
ity and whether the R1 side chain derives from a L-lactam
substrate or a L-lactam inhibitor of the L-lactamase. Not-
withstanding this, some R1 side chains bind tightly to
L-lactamases, leading to inhibitors with low Ki values for
these enzymes. These and related analogs are accessible
synthetically and may provide useful tools for studying
recognition and mechanism in L-lactamases. Several of
the compounds are highly active and selective, and they
reverse resistance to L-lactam antibiotics in pathogenic
bacteria in cell culture. Coupling interaction energies
with structure and synthesis may guide the design of
anti-resistance agents in this series.
5. Materials and methods
5.1. Synthesis and analysis
1H- and 13C-NMR spectra were recorded on a Brucker DPX-
200 MHz spectrometer and a Brucker-AMX-400 MHz respec-
tively: chemical shifts are reported in N values from TMS as
internal standard (s singlet, d doublet, t triplet, br broad). Cou-
pling constants (J) are given in Hz. Mass spectra were performed
on a Finnigan MAT-SSQ 710A mass spectrometer and a Hewlett
Packard 5872 (EI, 70 eV) mass spectrometer. Elemental analyses
were determined with a Carlo Erba Elemental Analyzer mod.
1106; elemental analyses for the compounds were within þ 0.5%
of the theoretical values. IR spectra were recorded with a Perkin
Elmer 1600 series FTIR; IR signals reported refer to C^O amide
stretching and N^H amide stretching respectively. Solvents were
dried and distilled before use; glassware was dried at 110‡C for
40 min. All reactions were conducted under inert atmosphere
unless otherwise speci¢ed. The common synthetic procedure is
presented in Scheme 1.
5.1.1. Pinacol chloromethaneboronate (1) [27]
Butyl lithium in hexane (2.5 M, 9.2 ml, 23 mmol) was added
dropwise to a stirred solution of bromochloromethane (1.5 ml, 23
mmol) and tri-tert-butylborate (2.3 ml, 21 mmol) in anhydrous
THF (25 ml) at 378‡C under nitrogen £ow; the resulting mixture
was allowed to react for 1 h. Thereafter, the reaction was
quenched at 378‡C with trimethylsilyl chloride (3.2 ml, 25.2
mmol), and the temperature gradually raised to room tempera-
ture (RT). After 16 h, a solution of pinacol (2.7 g, 23 mmol) in
ethyl ether (10 ml) was added dropwise, and the mixture was
stirred for an additional 3 h. The solution was diluted with water
(20 ml) and ethyl ether (10 ml), and the aqueous phase was
extracted with ethyl ether (3U10 ml). The combined organic
phases were washed with brine and dried (MgSO4). After removal
of the solvent under reduced pressure, the oily residue was dis-
tilled in vacuo (bp 55^56‡C/2 mm Hg) to yield 1 (3.08 g, 76%) as
a colorless oil. 1H-NMR (CDCl3): N 1.31 (12H, s, CH3), 2.97
(2H, s, CH2); 13C-NMR (CDCl3): N 25.4, 85.3; MS, m/z : 178^
176 (M), 163^161 (base peak), 145, 136^134, 120^118, 105^103,
85, 59, 43.
5.1.2. Pinacol N,NP-diformamidomethaneboronate (2) [28]
A solution of 1 (836 mg, 4.73 mmol) in anhydrous CH3CN
(2 ml) was added to a solution of sodium diformylamide (540 mg,
5.68 mmol) in anhydrous CH3CN (2 ml) and the mixture stirred
for 3 h at 80‡C. The white precipitate (NaCl) was centrifuged o¡,
the supernatant concentrated, and the residue distilled under re-
duced pressure to give 2 as a clear dense oil (735 mg, 73%), bp
Scheme 1. General scheme of synthesis of acylglycineboronic acids. See Section 4 for synthesis of boronic acids with other side chains.
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83‡C/1.5U1032 mm Hg. 1H-NMR (CDCl3): N 1.25 (12H, s,
CH3), 3.19 (2H, s, CH2), 8.86 (2H, s, COH); MS, m/z : 213
(M), 198, 183, 155 (base peak), 114, 126, 97 86.
5.1.3. Pinacol formamidomethaneboronate (3) [28]
Compound 2 (233 mg, 1.09 mmol) was dissolved in anhydrous
methanol (1.2 ml) and stirred at RT for 1 h, until a GLC analysis
showed disappearance of the starting material. The solution was
concentrated in vacuo and triturated with CH2Cl2. The viscous
oily residue crystallized overnight at 4‡C to give 3 (200 mg, 99%)
as a white solid, mp 55^56‡C. IR (KBr) 1629, 3375 cm31 ; 1H-
NMR (CDCl3): N 1.32 (12H, s, CH3), 2.93 (2H, d, J 4.5, CH2),
5.70 (1H, br, NH), 8.20 (1H, s, CHO); 13C-NMR (DMSO):
N 24.7, 82.3, 162.2; MS, m/z : 185 (M), 170, 154, 127 (base
peak), 86, 70, 59, 43.
5.1.4. Pinacol bis-(trimethylsilyl)-aminomethaneboronate (4)
According to the procedure described [29], lithium hexamethyl-
disilazane in THF (1.0 M, 4.6 ml, 4.6 mmol) was added dropwise
to a solution of 1 (800 mg, 4.6 mmol) in anhydrous ethyl ether
(6 ml) cooled at 378‡C under nitrogen. After stirring for 10 min
at 378‡C, the cooling bath was removed and the solution stirred
for 2 h at RT. The precipitate (LiCl) was centrifuged, the super-
natant concentrated under reduced pressure, and the oily residue
was distilled under reduced pressure (bp 80^81‡C/1 mm Hg) to
give 4 (780 mg, 57%) as a colorless oil. 1H-NMR (CDCl3): N 0.10
(18H, s, SiCH3), 1.26 (12H, s, CH3), 2.47 (2H, s, CH2); MS, m/z :
301 (M), 286, 228, 186 (base peak), 170, 112, 73, 59.
5.1.5. Pinacol acetamidomethaneboronate (5)
According to the procedure described [30], acetic acid (36.4 Wl,
0.63 mmol) and acetic anhydride (165 Wl, 1.75 mmol) were added
at 310‡C to a solution of 4 (150 mg, 0.5 mmol) in anhydrous
Et2O (3 ml) under inert atmosphere. After 1.5 h the solvent was
evaporated in vacuo, and the residue crystallized from Et2O/pen-
tane to give 5 (60 mg, 60%) as a white solid, mp 108‡C. IR (KBr)
1619, 3370 cm31 ; 1H-NMR (CDCl3): N 1.26 (12H, s, CH3), 2.07
(3H, s, COCH3), 2.56 (2H, d, J 4.4, CH2), 6.97 (1H, br, NH);
13C-NMR (DMSO): N 24.2, 25.1, 79.3, 174.3; MS, m/z : 199
(M), 184, 169, 141, 140 (base peak), 100, 99, 84, 83, 74, 55.
5.1.6. Reaction of pinacol bis-(trimethylsilyl)-
aminomethaneboronate (4) with acyl chlorides:
general procedure [31]
A solution of anhydrous methanol in THF (1 mmol, 2.5 M)
was added at 310‡C to a solution of 4 (1 mmol) in THF under
nitrogen. The cooling bath was removed, and the reaction mix-
ture was stirred for 1 h at RT. The reaction mixture was once
again cooled to 310‡C. A solution of the acyl derivative (1 mmol)
in THF was slowly added and allowed to react for the reported
time whereupon a GLC analysis indicated total disappearance of
4. The solvent was evaporated in vacuo and the residue puri¢ed
by crystallization.
5.1.7. Pinacol phenylacetamidomethaneboronate (6)
Phenylacetylchloride was allowed to react with 4 for 1 h. The
solvent was evaporated and the viscous oily residue crystallized
from hexane to give 6 (91% yield) as a pale yellow solid, mp
114‡C. IR (KBr) 1615, 3169 cm31 ; 1H-NMR (CDCl3): N 1.27
(12H, s, CH3), 2.59 (2H, d, J 2.6, BCH2), 3.68 (2H, s, PhCH2),
6.97 (1H, br, NH), 7.24^7.44 (5H, m, aromatic) ; 13C-NMR
(DMSO): N 24.9, 38.4, 80.4, 126.8, 128.4, 128.9, 134.7, 174.0;
MS, m/z : 275 (M), 260, 217, 176, 160, 142, 91 (base peak),
83.
5.1.8. Pinacol phenoxyacetamidomethaneboronate (7)
After 1 h at RT, the solvent was evaporated and the residue
crystallized from pentane to yield 7 (80%) as a white solid, mp
60‡C. IR (KBr) 1630, 3454 cm31 ; 1H-NMR (CDCl3): N 1.31
(12H, s, CH3), 2.92 (2H, d, J 4.5, BCH2), 4.55 (2H, s, OCH2),
6.77 (1H, br, NH), 6.92^7.10 (3H, m, aromatic), 7.30^7.40 (2H,
m, aromatic) ; 13C-NMR (DMSO): N 24.7, 66.1, 82.3, 114.8,
121.2, 129.4, 157.6, 169.0; MS, m/z : 291 (M), 276, 233 (base
peak), 176, 98, 94, 77.
5.1.9. Pinacol [(2-phenoxypropanoyl)amino]methaneboronate (8)
After 1 h at RT, the solvent was evaporated to a¡ord a white
solid residue which was triturated with n-pentane to a¡ord 8
(89%), mp 78‡C. IR (KBr) 1621, 3186; 1H-NMR (CDCl3):
N 1.28 (12H, s, CCH3), 1.61 (3H, d, J 6.8, CHCH3), 2.83 (2H,
d, J 4.5, CH2), 4.73 (1H, q, J 6.8, CHCH3), 6.65 (1H, br, NH),
6.91^7.08 (3H, m, aromatic), 7.27^7.38 (2H, m, aromatic) ; 13C-
NMR (DMSO): N 18.6, 24.6, 73.0, 82.4, 115.4, 121.1, 129.4,
157.1, 172.3; MS, m/z : 305 (M), 290, 247 (base peak), 184,
121, 112, 83, 77.
5.1.10. Pinacol [[(3-(2-chlorophenyl)-5-methyl-4-isoxazolyl)
carbonyl] amino] methaneboronate (9)
After 1 h at RT, the solvent was evaporated and the residue
crystallized from pentane to a¡ord 9 (92%) as white crystalline
solid, mp 91‡C. IR (KBr) 1622, 3060; 1H-NMR (CDCl3): N 1.21
(12H, s, CH3), 2.74 (2H, d, J 3.8, CH2), 2.81 (3H, s, CH3), 5.59
(1H, br, NH), 7.40^7.51 (4H, m, aromatic) ; 13C-NMR (DMSO):
N 12.2, 24.7, 82.0, 111.8, 127.1, 127.4, 129.6, 131.4, 131.6, 132.6,
159.5, 161.9, 170.5; MS, m/z : 377 (M), 341 (base peak), 318,
241, 215, 178, 111, 83.
5.1.11. Pinacol [(2-ethoxy-1-naphthoyl)amino]methaneboronic
acid (10)
After 16 h at RT, solvent was removed a¡ording a viscous
residue, which was puri¢ed by silica column chromatography
(elution: ethyl ether/ethyl acetate 1:1 v/v and then methanol) to
give the free boronic acid 10 (57%) as a white solid, mp 150‡C
(dec). IR (KBr) 1630, 3250; 1H-NMR (DMSO): N 1.32 (3H, t,
J 6.7, CH3), 2.80 (2H, d, J 4.9, BCH2), 4.20 (2H, d, J 6.7, OCH2),
7.20^8.00 (9H, m, aromatic, NH, OH); 13C-NMR (DMSO):
N 14.9, 64.8, 64.9, 115.4, 122.5, 123.7, 124.5, 126.6, 127.7, 128.2,
129.8, 131.1, 152.2, 166.5; MS, m/z : 273 (M), 229, 199, 171, 170,
155, 142, 127, 115 (base peak), 89, 88.
5.1.12. Pinacol K-thienylacetamidomethaneboronate (11)
After 1 h at RT, the solvent was removed and the residue
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crystallized from ethyl ether/pentane yielding 7 (62%) as a white
solid, mp 86^87‡C. IR (KBr) 1619, 3169; 1H-NMR (CDCl3):
N 1.28 (12H, s, CH3), 2.66 (2H, d, J 3.1, BCH2), 3.87 (2H, s,
ArCH2), 6.10 (1H, br, NH), 6.97^7.03 (2H, m, aromatic), 7.28
(1H, dd, J 5.0, 1.5, S^CH); 13C-NMR (DMSO): N 24.8, 33.6,
81.3, 125.2, 126.4, 126.6, 136.2, 172.0; MS, m/z : 281 (M), 266,
223, 182, 166, 142, 97 (base peak), 83, 55.
5.1.13. Pinacol chloroacetamidomethaneboronate (12)
After 1.5 h at RT, the solvent was evaporated in vacuo a¡ord-
ing 12 as a clear viscous oil (100%), which was used without
further puri¢cation. 1H-NMR (CDCl3): N 1.31 (12H, s, CH3),
2.90 (2H, d, J 4.4, BCH2), 4.09 (2H, s, CH2Cl), 6.75 (1H, br,
NH). 13C-NMR (CDCl3): N 25.5, 43.1, 84.9, 167.6. MS, m/z :
235^233 (M), 220^218, 198, 177^175, 136^134, 119^117 (base
peak), 98, 83, 55.
5.1.14. Pinacol (4-pyridil)thioacetamidomethaneboronate
hydrochloride (13)
A solution of 4-mercaptopyridine (31 mg, 0.28 mmol) in anhy-
drous DMF (0.5 ml) was added under vigorous stirring to a so-
lution of 12 (66 mg, 0.28 mmol) in anhydrous DMF (2 ml). After
3.5 h at 100‡C, the solvent was evaporated under reduced pres-
sure. The residue was crystallized from ethyl ether/pentane to give
13 as a white crystalline solid (90%), mp 186‡C dec. IR (KBr)
1665, 3283 and 2550 (N^H stretching); 1H-NMR (DMSO):
N 1.16 (12H, s, CH3), 2.52 (2H, d, J 4.3, BCH2), 4.08 (2H, s,
SCH2), 7.85 (2H, dd, J 7.0, 1.4, H(3), H(5) aromatic), 8.52 (1H,
br, NH), 8.62 (2H, dd, J 7.0, 1.2, H(2), H(6) aromatic) ; 13C-
NMR (DMSO): N 24.6, 33.1, 82.8, 122.3, 140.4, 160.8, 167.0;
MS, m/z : 308 (M) , 293, 250, 209, 198, 152, 140, 125 (base
peak), 111, 98, 83.
5.1.15. Pinacol [[2-amino-K-[1-(tert-butoxycarbonyl)-
1-methylethoxyimino]-4-thiazoleacetyl]amino]
methaneboronate (14)
Triethylamine (184 Wl, 1.32 mmol) and isobutylchloroformate
(171 Wl, 1.32 mmol) were added to a solution of (Z)-2-amino-
K-[1-(tert-butoxycarbonyl)-1-methylethoxyimino]-4-thiazoleacetic
acid (438 mg, 1.32 mmol) in anhydrous THF (30 ml) at 0‡C
and allowed to react under inert atmosphere for 40 min. A solu-
tion of 4 (400 mg, 1.32 mmol) in anhydrous THF (4 ml), previ-
ously treated with anhydrous methanol (1.32 mmol) was added
at the same temperature. After 20 min the temperature was raised
to RT and the mixture allowed to react for 1 h. The white
precipitate (ammonium chloride) was centrifuged, and the super-
natant was evaporated under reduced pressure. The residue was
crystallized from CH2Cl2/pentane to give 14 as a white crystalline
solid (80%), mp 188^190‡C dec. IR (KBr) 1630, 1724, 3322;
1H-NMR (CDCl3): N 1.32 (12H, s, CH3), 1.47 (9H, s,
C(CH3)3), 1.57 (6H, s, CH3CCO), 1.81 (2H, br, NH2), 3.00
(2H, d, J 4.4, CH2NH), 6.98 (1H, t J 4.4, NH), 7.08 (1H, s,
aromatic) ; 13C-NMR (CDCl3) : N 24.4, 25.6, 28.8, 82.6, 83.5,
85.0, 112.0, 143.3, 149.6, 163.7, 170.2, 174.5; MS, m/z : 468
(M), 453, 410, 367, 354, 309, 285, 251, 226, 209, 184, 142, 126
(base peak), 98, 83, 59.
5.1.16. Pinacol [[2-amino-K-(1-carboxy-1-methylethoxyimino)-
4-thiazoleacetyl] amino] methaneboronate tri£uoroacetic
salt (15)
Compound 14 (200 mg, 0.43 mmol) was dissolved in tri£uoro-
acetic acid (2.5 ml). After 50 min, the excess was evaporated
under reduced pressure to give a dense oil which was crystallized
from CH2Cl2/n-hexane to a¡ord a yellowish crystalline solid
(80%), mp 161‡C (dec). IR: 1661, 3286. 1H-NMR (CDCl3):
N 1.32 (12H, s, CH3), 1.69 (6H, s, CH3CCO), 2.99 (2H, d, J 4.3,
CH2), 5.76 (3H, b, NH3 ), 7.31 (1H, s, aromatic), 7.92 (1H, t,
J 4.3, NH), 8.24 (1H, b, COOH). 13C-NMR N (CDCl3): 24.2,
25.4, 85.1, 85.8, 110.9, 133.4, 142.2, 160.1, 170.9, 176.3. MS,
m/z : 412 (M), 397, 354, 310, 295, 268, 252, 229, 226, 221, 198,
185, 153, 129, 125, 103, 98 (base peak), 83, 69, 59.
5.2. Enzyme puri¢cation
AmpC from Escherichia coli was expressed and puri¢ed to
homogeneity as described [12]. The TEM-1 gene was ampli¢ed
from pBR322 by PCR and expressed from a pAlterEx II plasmid
(Promega, Madison, WI, USA) from transformed E. coli JM109
cells. TEM-1 was expressed and puri¢ed using a procedure modi-
¢ed from Vanhove et al. [32] ; a full description will be published
elsewhere.
5.3. Enzyme inhibition assays
The pinacol esters of the acylglycineboronic acids were hydro-
lyzed to the free acids by dissolving them in 50 mM phosphate
bu¡er at pH 7.0 [33] at a concentration of 10 mM; more dilute
stocks (1 mM to 100 WM) were subsequently prepared as neces-
sary. Kinetic measurements with AmpC were performed using
cephalothin as a substrate [11]. Reactions were initiated by the
addition of 1.5 nM enzyme. No incubation e¡ect was detected for
any compound, consistent with earlier studies [11,25]. IC50 values
were determined at 100 WM substrate concentration.
TEM-1 enzyme assays used 100 WM furylacryloylamidopenicil-
lanic acid as substrate, monitoring absorbance changes at 340 nm
on an HP8453 spectrophotometer. Reactions were initiated with
addition of 0.3 nM enzyme, using the same bu¡er as in the
AmpC assays.
The Ki values for compounds 3^14 were obtained by compar-
ison of progress curves in the presence and absence of inhibitor
[25]. Su⁄cient inhibitor was used to give at least 50% inhibition.
This method correlates well with full Ki analysis through coupled
substrate and inhibitor concentration variation [11]. For com-
pound 9, a Ki of 170 þ 10 nM, consistent with the value of 160
nM determined by progress curve analysis, was also determined
by Lineweaver^Burk analysis of multiple substrate and inhibitor
concentrations (data not shown).
The selectivity of compounds 3 and 15 for L-lactamases was
determined by measuring their activity against K-chymotrypsin
(bovine pancreatic), L-trypsin (bovine pancreatic), and elastase
(porcine pancreatic), all from Sigma (St. Louis, MO, USA). Sub-
strates for K-chymotrypsin (N-benzoyl-L-tyrosine ethyl ester,
BTEE) and L-trypsin (N-benzoyl-L-arginine ethyl ester, BAEE)
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were also purchased from Sigma. The elastase substrate used
(elastase substrate 1, MeOSuc-Ala-Ala-Pro-Val-pNA) was pur-
chased from Calbiochem (San Diego, CA, USA). Substrates
were diluted from 10 mM DMSO stock solutions, and all reac-
tions were performed in 50 mM potassium phosphate bu¡er, pH
7.0, 25‡C. For K-chymotrypsin, 140 WM of BTEE was used, the
reactions were initiated by addition of 5 Wl of a 0.1 mg/ml enzyme
stock solution, and monitored at 260 nm. For L-trypsin, 200 WM
of BAEE was used, the reactions were initiated by the addition of
5 Wl of a 0.2 mg/ml enzyme stock solution, and monitored at 260
nm. For elastase, 640 WM of elastase substrate was used, the
reactions were initiated by the addition of 30 Wl of a 0.2 mg/ml
enzyme stock solution, and monitored at 385 nm. Initial rate ¢ts
to the absorbance data for the ¢rst 150 s of each reaction were
used to determine reaction velocities.
5.4. Crystal growth and structure determination
Co-crystals of 9 and 11 were grown by vapor di¡usion in
hanging drops equilibrated over 1.7 M potassium phosphate bu¡-
er (pH 8.7) using microseeding techniques. The initial concentra-
tion of protein in the drop was 95 WM, and the concentrations of
each inhibitor were 586 WM. The inhibitors were added to the
crystallization drop in a 2% DMSO, 1.7 M potassium phosphate
bu¡er (pH 8.7) solution. Crystals appeared within 3^5 days after
equilibration at 23‡C.
Data were collected on the DND-CAT beam line (5IDB) of the
Advanced Photon Source at Argonne National Lab at 100 K
using a 162 mm Mar CCD detector. Prior to data collection,
crystals were immersed in a cryoprotectant solution of 20% su-
crose, 1.7 M potassium phosphate, pH 8.7, for about 20 s, then
£ash-cooled in liquid nitrogen. Each data set was measured from
a single crystal.
Re£ections were indexed, integrated, and scaled using the HKL
program suite [34] (Table 3). The space group was C2, with two
AmpC molecules in the asymmetric unit. Each AmpC molecule
contained 358 residues. The structure was determined by molec-
ular replacement using an AmpC/boronic acid complexed struc-
ture [13], with inhibitor and water molecules removed, as the
initial phasing model. The model was re¢ned using the maximum
likelihood target in CNS and included a bulk solvent correction
[35]. Sigma A-weighted electron density maps were calculated
using CNS, and manual rebuilding was done in the program O
[36]. The inhibitor was built into the observed di¡erence density
in each active site of the asymmetric unit, and the structure of the
complex was further re¢ned using CNS (Table 3). All atoms of
inhibitor 9 were re¢ned with an occupancy of 1.0. All atoms of
inhibitor 11 were re¢ned with an occupancy of 1.0, except for
atoms of the thiophene ring (C9, C10, C11 and S1) which were
re¢ned with an occupancy of 0.5 for each of the two possible
conformations.
5.5. Microbiology
Compounds 10 and 15 were tested for synergy with L-lactams
against pathogenic bacteria that are sensitive to L-lactams and to
pathogenic bacteria that are resistant to L-lactams through pro-
duction of either Group I or Group II L-lactamases. Bacterial
strains tested included: E. cloacae EB5 (L-lactamase negative),
E. cloacae 265A (Group I L-lactamase hyper-producer), and
S. aureus V41 (Group II L-lactamase producer). MIC values
were determined with Mueller^Hinton Broth II using the micro-
dilution method according to NCCLS guidelines [37]. The L-lac-
tams cefotaxime and ceftazidime were used with E. cloacae, and
amoxicillin was used with S. aureus. Checkerboard assays were
performed to study the synergistic e¡ects.
Disk di¡usion plate assays were performed as follows. E. clo-
acae EB5 and E. cloacae 265A were each grown to log-phase and
then diluted in TY broth to a turbidity equivalent to McFarland
1. The cultures were further diluted 100-fold into melted TY agar
medium and allowed to solidify in Falcon 150U25 mm plates.
The plates were then spotted with ceftazidime (25 Wg per disk for
the EB5 plate and 50 Wg per disk for the 265A plate; upper disks)
and 100 Wg of 15 (lower disks on the left) and 100 Wg of 10 (lower
disks on the right). After overnight incubation at 35 ‡C, the zones
of inhibition were imaged.
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